"Despite significant reduction in the pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fatal decompensated heart failure events, which was the trial's primary endpoint"
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-10
-
- There are more pages in this discussion • 1,013 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.008(0.71%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $361.6K | 337.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 29056 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 5787 | 9 |
View Market Depth
| Last trade - 10.40am 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |